Find-Health-Articles.com - making medical research available to everyone
Research article summary (published 30 Jan 2009):

WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation.

Full Abstract

In-vitro studies have shown that WAY 100635 is not only a potent 5-HT1A antagonist, but also has high affinity and efficacy at the dopamine D(4) receptor. Nevertheless, the behavioral effects of this compound have not been investigated. This study sought to characterize the discriminative stimulus effects produced by WAY 100635. Male Sprague-Dawley rats were trained in a two-lever, fixed ratio 50, food-reinforced task with WAY 100635 (10 micromol/kg) as a discriminative stimulus. Substitution tests with different doses of WAY 100635 and (-)-pindolol, and combination tests with two 5-HT1A agonists, 8-OH-DPAT and LY 293284; and two dopamine D(4) antagonists, sonepiprazole and A-381393, were performed. Rats trained with a low dose (0.74 micromol/kg) of WAY 100635 could not learn the discrimination task after more than 3 months of sessions. Rats trained to discriminate 10 micromol/kg of WAY 100635 from saline achieved the criterion of accuracy after approximately 35 training sessions. WAY 100635 (2.5-10 micromol/kg) produced a dose-dependent increase in WAY 100635-appropriate responding, with a mean effective dose of 3.44 micromol/kg, whereas saline or pindolol (5-25 micromol/kg) administration resulted in 0% drug lever responding. Pretreatment with the 5-HT(1A) agonists 8-OH-DPAT or LY 293284 did not modify the WAY 100635 curve, but pretreatment with the selective dopamine D(4) antagonists sonepiprazole or A-381393 completely blocked the cue. These results indicate that the discriminative stimulus effect produced by WAY 100635 is mediated by activation of dopamine D(4) receptors.

 

Author information

Author/s: Marona-Lewicka, Danuta (D); Nichols, David E (DE);

Affiliation: Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Purdue University, West Lafayette, Indiana 47907-2091, USA.

Grants: DA02189 (Agency:NIDA NIH HHS)

Journal and publication information

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal: Behavioural pharmacology (Behav Pharmacol), published in England. (Language: eng)

Reference: 2009-Feb; vol 20 (issue 1) : pp 114-8

Dates: Created 2009/01/30; Completed 2009/03/03; Revised 2009/07/07;

PMID: 19179855, status: MEDLINE (last retrieval date: 7/24/2009, IMS Date: 24 Jul 2009 00:00:00)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Associated Chemicals: 2-(4-(3,4-dimethylphenyl)piperazin-1-ylmethyl)-1H-benzimidazole (0) ; Benzimidazoles (0) ; Piperazines (0) ; Pyridines (0) ; Sulfonamides (0) ; Tryptamines (0) ; Receptor, Serotonin, 5-HT1A (112692-38-3) ; Pindolol (13523-86-9) ; Receptors, Dopamine D4 (137750-34-6) ; LY 293284 (141318-62-9) ; WAY 100635 (146714-97-8) ; U 101387 (170858-33-0) ; 8-Hydroxy-2-(di-n-propylamino)tetralin (78950-78-4)

Related articles

These are the highest related articles currently in the database:

See 100+ related articles.

Related Article Map

10/30/1973
3/18/2007
Higher Relevance Score (100)
Lower Relevance Score (63)

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.

© Advanogy LLC 2003-2009 - All rights reserved. Terms of Use | Contact Us | Index